Equities research analysts at Dougherty & Co initiated coverage on shares of Baxter International (NYSE: BAX) in a research note issued to investors on Thursday. They set a “neutral” rating on the stock.
Separately, analysts at Standpoint Research initiated coverage on shares of Baxter International in a research note to investors on Thursday. They set a “buy” rating and a $59.00 price target on the stock. Analysts at RBC Capital (NYSE: RY) downgraded shares of Baxter International to an “outperform” rating in a research note to investors on Tuesday, December 20th. Also, analysts at Piper Jaffray (NYSE: PJC) cut their price target on shares of Baxter International to $66.00 in a research note to investors on Friday, December 16th.
Baxter International Inc. (Baxter) is a global, diversified healthcare company. The Company, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. It operates in three segments: The BioScience, Medication Delivery and Renal segments. Baxter is engaged in the medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctorsâ€™ offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products in 27 countries and sells them in more than 100 countries. In November 2011, the Company acquired Baxa Corporation.
Shares of Baxter International traded up 0.28% during mid-day trading on Thursday, hitting $49.80. Baxter International has a 52 week low of $47.55 and a 52 week high of $62.50. The stock’s 50-day moving average is $49.84 and its 200-day moving average is $54.54. The company has a market cap of $28.081 billion and a price-to-earnings ratio of 13.14.